Clinical trials: Venous Thromboembolic Disease
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Venous Thromboembolism, Antenatal Deep Vein Thrombosis
LMWH Compliance in Pregnancy
This is a prospective chart study that will aim to assess objective data on compliance levels to low molecular weight heparin (LMWH) injections among pregnant and postnatal women undergoing VTE thromboprophylaxis treatment at…
- Trial name
- NCT05066867
- Testing
- Smart sharps bin - collects data on compliance
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cork University Maternity Hospital
Pulmonary Embolism
Crux Biomedical Vena Cava Filter Study - United States
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 2 (NCT01120509)
- Testing
- Inferior Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 88 people
- Sponsor
- Crux Biomedical
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Deep Vein Thrombosis (DVT)
Improving Emergency Department Testing for Deep Vein Thrombosis
This observational study will use a new way to test for deep vein thrombosis (DVT) of the leg. A DVT is a blood clot in the leg and is a medical problem that can cause swelling, pain, and redness.
- Trial name
- NCT06195787
- Where
- Canada
- Volunteers
- 458 people
- Sponsor
- Dr. Kerstin de Wit
Pulmonary Embolism
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System
The Bard® Denali™ Retrievable Inferior Vena Cava (IVC) study is a prospective, multi-center study which is intended to provide evidence of safety of the placement and retrieval of the Bard® Denali™ Retrievable Inferior Vena Cava…
- Trial name
- NCT01305564
- Testing
- Denali inferior vena cava filter
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- C. R. Bard
Breast Neoplasms, Venous Thromboembolism
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
The aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).
- Trial name
- HEMOBREAST (NCT03381963)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolism
Screening for Occult Malignancy in Idiopathic Venous Thromboembolism
Prospective controlled randomized study. Aim of this study is to assess the feasibility and sensitivity of CT scanning of the thorax, abdomen and pelvis for the detection of occult cancer in patients with idiopathic venous…
- Trial name
- NCT00361647
- Testing
- Diagnostic screening for occult malignancy
- Where
- Italy
- Sponsor
- University of Padova
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Venous Thromboembolism
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12…
- Trial name
- NCT00439725
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 322 sites in United States, Australia and 31 more
- Volunteers
- 1,197 people
- Sponsor
- Bayer
Venous Thromboembolism
StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce…
- Trial name
- SAVER (NCT02679664)
- Testing
- Rosuvastatin
- Where
- 6 sites in Canada, Norway
- Volunteers
- 312 people
- Sponsor
- Ottawa Hospital Research Institute
Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis
Apixaban in Thrombocytopenia
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
- Trial name
- NCT06886516
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rushad Patell
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Venous Thromboembolism, Deep Venous Thrombosis
Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
Blood clots that form in the extremities (deep venous thrombosis) and lungs (pulmonary embolus) are feared complications of reconstructive surgery.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
- Trial name
- NCT02687204
- Testing
- Twice daily enoxaparin prophylaxis, Real time dose adjustment
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Utah
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Venous Thromboembolism
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736420
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 78,605 people
- Sponsor
- Brigham and Women's Hospital
The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer.
- Conditions
- The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to, Prophylaxis Given for 8±2 Days After Planned Laparoscopic, Surgery for Colorectal Cancer.
- Trial name
- PRO-LAPS I (NCT01589146)
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Of Perugia
Venous Thromboembolism
Electronic Strategies to Enhance Venous Thromboemboli (VTE) Prophylaxis in Hospitalized Medical Patients
Venous thromboemboli (VTE) are abnormal blood clots that commonly form in the blood vessels of the legs or lungs. They can block normal blood flow, damage organs, and even cause death.
- Trial name
- E-SENTRY (NCT01401725)
- Testing
- Electronic Order Entry System + CDSS, Electronic Order Entry System Only, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Conditions
- Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
- Trial name
- PERSEUS (NCT07855679)
- Testing
- Routine clinical care (no study intervention)
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim